drugset / Trial / NCT01879618

Use Of Fragmin In Hemodialysis

NCT01879618

Phase 3 Completed 152 enrolled Pfizer
NaSingle-groupOpen-labelTreatment

Summary

The study will determine if the Fragmin dose can be adjusted to suit the clinical needs of patients during dialysis.

Timeline

Start
2013-10
Primary completion
2016-03
Completion
2016-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Dalteparin sodium Other / unclassified 5000 iu